The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister Mette Frederiksen to discuss preparations for a possible trade conflict with the United States over Greenland.

Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $52.5 to $120.0 for Novo Nordisk over the last 3 months.

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO stock as a strong buy.

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the company said semaglutide 7.2 milligram (mg) injections over a 72-week period resulted in an average weight loss of 20.7%, better than the 17.5% weight loss achieved in a prior trial of semaglutide 2.4 mg injections.

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price

COPENHAGEN - The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations for a possible trade conflict with the United States over Greenland with Denmark's Prime Minister Mette Frederiksen on Thursday.

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

London-based megabank HSBC may be recognizable to some U.S. consumers, but elsewhere, it is a well-known name that provides banking and financial services worldwide. Like other major enterprises in the sector, it operates a diversified business, including personal and commercial banking, wealth management and capital markets segments.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug